ORBIMED ADVISORS LLC Q2 2019 Filing
Filed August 14, 2019
Portfolio Value
$6.5B
Holdings
123
Report Date
Q2 2019
Filing Type
13F-HR
All Holdings (123 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | XENEXENON PHARMACEUTICALS INC | 634,812 | $6.3B | 96.93% | |
| 102 | SPROSPERO THERAPEUTICS INC | 507,471 | $5.8B | 90.46% | |
| 103 | ADPTADAPTIVE BIOTECHNOLOGIES COR | 120,000 | $5.8B | 89.76% | |
| 104 | —MEDICINES CO | 151,515 | $5.5B | 85.58% | |
| 105 | ADAPYADAPTIMMUNE THERAPEUTICS PLC | 1,350,655 | $5.4B | 84.09% | |
| 106 | NTLAINTELLIA THERAPEUTICS INC | 327,600 | $5.4B | 83.06% | |
| 107 | SELBUSDSELECTA BIOSCIENCES INC | 2,879,064 | $5.2B | 79.82% | |
| 108 | RAREULTRAGENYX PHARMACEUTICAL IN | 79,607 | $5.1B | 78.29% | |
| 109 | —AERPIO PHARMACEUTICALS INC | 5,193,946 | $4.7B | 73.19% | |
| 110 | CTIC1USDCTI BIOPHARMA CORP | 5,000,000 | $4.3B | 66.55% | |
| 111 | —MENLO THERAPEUTICS INC | 673,700 | $4.0B | 62.49% | |
| 112 | STOKSTOKE THERAPEUTICS INC | 130,000 | $3.8B | 58.73% | |
| 113 | —NOVUS THERAPEUTICS INC | 3,183,314 | $3.2B | 49.79% | |
| 114 | —REALM THERAPEUTICS PLC | 1,021,484 | $2.9B | 44.45% | |
| 115 | ACADACADIA PHARMACEUTICALS INC | 101,900 | $2.7B | 42.19% | |
| 116 | DVAXDYNAVAX TECHNOLOGIES CORP | 583,500 | $2.3B | 36.05% | |
| 117 | SNDXSYNDAX PHARMACEUTICALS INC | 212,000 | $2.0B | 30.57% | |
| 118 | —AVROBIO INC | 106,000 | $1.7B | 26.70% | |
| 119 | —MARINUS PHARMACEUTICALS INC | 398,101 | $1.7B | 25.58% | |
| 120 | —NUVECTRA CORP | 350,000 | $1.2B | 18.17% | |
| 121 | —FLEXION THERAPEUTICS INC | 89,919 | $1.1B | 17.13% | |
| 122 | —BIOLINERX LTD | 1,038,600 | $379.0M | 5.87% | |
| 123 | —MEDIGUS LTD | 15,000 | $37.0M | 0.57% |
PreviousPage 2 of 2